AI Chat Paper
Discover the SciOpen Platform and Achieve Your Research Goals with Ease.
Search articles, authors, keywords, DOl and etc.
{{expandStatus?'Exit ':''}}Advanced Search
(
This study assessed the safety and efficacy of nirmatrelvir‐ritonavir (Paxlovid®) and azvudine when administered sequentially or concomitantly in patients with coronavirus 2019 (COVID‐19) caused by the Omicron variant.
Ninety‐three patients confirmed to be infected with the Omicron variant by nucleic acid detection were retrospectively investigated. Information was collected on general health status, medication, and adverse drug reactions (ADRs) according to whether nirmatrelvir‐ritonavir and azvudine were administered sequentially or concomitantly. Data on times of onset, clinical manifestations, and outcomes of ADRs and on conversion to a negative nucleic acid test were also recorded.
Possible ADRs were recorded in 41 patients (44.1%). There were 22 gastrointestinal reactions in 18 patients and 18 hematological abnormalities in 16 after sequential or concomitant treatment with nirmatrelvir‐ritonavir and azvudine. Liver enzyme levels increased in nine cases and creatinine clearance decreased in two. Cases of atrial fibrillation (n = 1), sleep disorder (n = 2), rash (n = 2), dizziness (n = 1), and weakness (n = 5) were also documented. Only vomiting, poor appetite, diarrhea, xerostomia, bitter taste, and rash were considered probable ADRs; others were thought to be possible ADRs. In all cases, the nucleic acid test did not turn negative after the first antiviral was applied. The nucleic acid test of 28 patients did not turn negative before discharge. The remaining 65 patients (69.9%) returned a negative nucleic acid test after receiving the second antiviral agent.
Treatment with nirmatrelvir‐ritonavir and azvudine is safe and effective whether administered sequentially or concomitantly in patients with COVID‐19 caused by the Omicron variant.
Vitiello A, Ferrara F, Auti AM, Di Domenico M, Boccellino M. Advances in the Omicron variant development. J Intern Med. 2022;292(1):81–90. https://doi.org/10.1111/joim.13478
Owen DR, Allerton CMN, Anderson AS, Aschenbrenner L, Avery M, Berritt S, et al. An oral SARS‐CoV‐2 Mpro inhibitor clinical candidate for the treatment of COVID‐19. Science. 2021;374(6575):1586–93. https://doi.org/10.1126/science.abl4784
Sheahan TP, Sims AC, Zhou S, Graham RL, Pruijssers AJ, Agostini ML, et al. An orally bioavailable broad‐spectrum antiviral inhibits SARS‐CoV‐2 in human airway epithelial cell cultures and multiple coronaviruses in mice. Sci Transl Med. 2020;12(541):eabb5883. https://doi.org/10.1126/scitranslmed.abb5883
Zhang JL, Li YH, Wang LL, Liu HQ, Lu SY, Liu Y, et al. Azvudine is a thymus‐homing anti‐SARS‐CoV‐2 drug effective in treating COVID‐19 patients. Signal Transduct Target Ther. 2021;6(1):414. https://doi.org/10.1038/s41392‐021‐00835‐6
Ren Z, Luo H, Yu Z, Song J, Liang L, Wang L, et al. A randomized, open‐label, controlled clinical trial of azvudine tablets in the treatment of mild and common COVID‐19, a pilot study. Adv Sci. 2020;7(19):e2001435. https://doi.org/10.1002/advs.202001435
Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239–45. https://doi.org/10.1038/clpt.1981.154
Yang H, Wang Z, Jiang C, Zhang Y, Zhang Y, Xu M, et al. Oral azvudine for mild‐to‐moderate COVID‐19 in high risk, nonhospitalized adults: results of a real‐world study. J Med Virol. 2023;95(7):e28947. https://doi.org/10.1002/jmv.28947
Cao Z, Gao W, Bao H, Feng H, Mei S, Chen P, et al. VV116 versus nirmatrelvir‐ritonavir for oral treatment of Covid‐19. N Engl J Med. 2023;388(5):406–17. https://doi.org/10.1056/NEJMoa2208822
Zhao Q, Zheng B, Han B, Feng P, Xia Z, Jiang H, et al. Is azvudine comparable to nirmatrelvir‐ritonavir in real‐world efficacy and safety for hospitalized patients with COVID‐19? A retrospective cohort study. Infect Dis Ther. 2023;12(8):2087–102. https://doi.org/10.1007/s40121‐023‐00845‐7
Yu B, Chang J. Azvudine (FNC): a promising clinical candidate for COVID‐19 treatment. Signal Transduct Target Ther. 2020;5(1):236. https://doi.org/10.1038/s41392‐020‐00351‐z
Li M, Zhang QS, Liu XL, Wang HL, Liu W. Adverse events associated with nirmatrelvir/ritonavir: a pharmacovigilance analysis based on FAERS. Pharmaceuticals. 2022;15(12):1455. https://doi.org/10.3390/ph15121455
Akinosoglou K, Schinas G, Gogos C. Oral antiviral treatment for COVID‐19: a comprehensive review on nirmatrelvir/ritonavir. Viruses. 2022;14(11):2540. https://doi.org/10.3390/v14112540
Tiseo G, Barbieri C, Galfo V, Occhineri S, Matucci T, Almerigogna F, et al. Efficacy and safety of nirmatrelvir/ritonavir, molnupiravir, and remdesivir in a real‐world cohort of outpatients with COVID‐19 at high risk of progression: the PISA outpatient clinic experience. Infect Dis Ther. 2023;12(1):257–71. https://doi.org/10.1007/s40121‐022‐00729‐2
Hammond J, Leister‐Tebbe H, Gardner A, Abreu P, Bao W, Wisemandle W, et al. Oral nirmatrelvir for high‐risk, nonhospitalized adults with Covid‐19. N Engl J Med. 2022;386(15):1397–408. https://doi.org/10.1056/NEJMoa2118542
Rosenke K, Lewis MC, Feldmann F, Bohrnsen E, Schwarz B, Okumura A, et al. Combined molnupiravir‐nirmatrelvir treatment improves the inhibitory effect on SARS‐CoV‐2 in macaques. JCI Insight. 2023;8(4):e166485. https://doi.org/10.1172/jci.insight.166485
Gidari A, Sabbatini S, Schiaroli E, Bastianelli S, Pierucci S, Busti C, et al. The combination of molnupiravir with nirmatrelvir or GC376 has a synergic role in the inhibition of SARS‐CoV‐2 replication in vitro. Microorganisms. 2022;10(7):1475. https://doi.org/10.3390/microorganisms10071475
This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
京公网安备11010802044758号